<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13330">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976507</url>
  </required_header>
  <id_info>
    <org_study_id>121204</org_study_id>
    <nct_id>NCT01976507</nct_id>
  </id_info>
  <brief_title>Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism</brief_title>
  <official_title>Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic
      event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of
      dabigatran use for peri-procedural anti-coagulation after left atrial catheter
      radiofrequency ablation, or cryoablation procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Frequency of major bleeding complications and thrombo-embolic events in patients administered dabigatran following RF ablation.</measure>
    <time_frame>Within 4 months following procedure (+/- 4 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dabigatran serum drug levels in patients experiencing a major bleeding or thrombo-embolic event.</measure>
    <time_frame>Within 4 months following procedure (+/- 4 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of minor bleeding events</measure>
    <time_frame>Within 4 months following procedure (+/- 4 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate mesylate</intervention_name>
    <arm_group_label>dabigatran etexilate mesylate</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female sex, age 18-85 years.

          -  Negative pregnancy test for women of childbearing potential

          -  Planned pulmonary vein isolation by antral radiofrequency or cryoablation for
             paroxysmal or persistent atrial fibrillation, non-valvular atrial fibrillation
             (NVAF), or left atrial flutter following prior left atrial ablation procedures

          -  CHADS2 score of 0-6 or CHADS2-VASc score 0-9

          -  Vascular hemostasis within 4-6 hours of sheath pull

          -  Able to give informed consent

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Currently participating in another clinical treatment trial

          -  History of hereditary hemophilias

          -  Presence of active bleeding

          -  End stage renal disease, CrCl&lt;15 mL/min

          -  Prior treatment failure of dabigatran (stroke or systemic thromboembolism while on
             therapeutic dabigatran)

          -  Known allergic reaction to dabigatran etexilate

          -  Intolerance to dabigatran, if medication na√Øve, or other contra-indications as per
             the USPI.

          -  Pregnancy

          -  History of non-compliance

          -  Inability to follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher R Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherry Bowman, RN</last_name>
    <phone>615-875-5500</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Ellis, MD</last_name>
      <email>christopher.ellis@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher R Ellis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean P Whalen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Christopher Ellis</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
